Clinical Trial Update: Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update outlines a Phase 1/2 study evaluating sequential FOLFOX-HAIC-TACE with sintilimab and bevacizumab as neoadjuvant therapy before surgi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Bevacizumab (bevacizumab)
• Leucovorin (folinic acid)
• OXALIPLATIN (Oxaliplatin)
• Sintilimab (sintilimab)

Snippet

Sponsor: BinYong Liang | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING